CoChat
Sign Up
Cited by 224Childhood Cancer Survivors' Quality of LifeGrowth Hormone and Insulin-like Growth FactorsPituitary Gland Disorders and Treatments

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society* Clinical Practice Guideline

Open access
Sklar, Charles A, Antal, Zoltan, Chemaitilly, Wassim, Cohen, Laurie E, Follin, Cecilia, Meacham, Lillian R, Murad, M Hassan·2018·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2018-01175
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To formulate clinical practice guidelines for the endocrine treatment of hypothalamic-pituitary and growth disorders in survivors of childhood cancer. Participants: An Endocrine Society-appointed guideline writing committee of six medical experts and a methodologist. Conclusions: Due to remarkable improvements in childhood cancer treatment and supportive care during the past several decades, 5-year survival rates for childhood cancer currently are >80%. However, by virtue of their disease and its treatments, childhood cancer survivors are at increased risk for a wide range of serious health conditions, including disorders of the endocrine system. Recent data indicate that 40% to 50% of survivors will develop an endocrine disorder during their lifetime. Risk factors for endocrine complications include both host (e.g., age, sex) and treatment factors (e.g., radiation). Radiation exposure to key endocrine organs (e.g., hypothalamus, pituitary, thyroid, and gonads) places cancer survivors at the highest risk of developing an endocrine abnormality over time; these endocrinopathies can develop decades following cancer treatment, underscoring the importance of lifelong surveillance. The following guideline addresses the diagnosis and treatment of hypothalamic-pituitary and growth disorders commonly encountered in childhood cancer survivors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-01175

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Historically, a theoretical concern for risk of primary tumor recurrence or secondary neoplasia related to GH use led to caution, and delays of a year following treatment for some brain tumors.

    “historically, a theoretical concern for risk of primary tumor recurrence or secondary neoplasia related to GH use led to caution, and delays of a year following treatment for some brain tumors (28)”

    From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [28]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 100

  1. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2014; 14(1):61-70.
  2. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan- Lottick NS, Schwartz CL, Leisenring W, Robison LL; Childhood Cancer Survivor Study. Chronic health conditions in adult sur- vivors of childhood cancer. N Engl J Med. 2006;355(15): 1572-1582.
  3. de Fine Licht S, Winther JF, Gudmundsdottir T, Holmqvist AS, Bonnesen TG, Asdahl PH, Tryggvadottir L, Anderson H, Wesenberg F, Malila N, Holm K, Hasle H, Olsen JH; ALiCCS Study Group. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a pop- ulation-based cohort study. Lancet. 2014;383(9933):1981-1989.
  4. Mostoufi-Moab S, Seidel K, Leisenring WM, Armstrong GT, Oeffinger KC, Stovall M, Meacham LR, Green DM, Weathers R, Ginsberg JP, Robison LL, Sklar CA. Endocrine abnormalities in aging survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2016;34(27):3240-3247.
  5. Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A, Papadopoulos E, Sklar C. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant. 1995;15(1):71-76.
  6. Oudin C, Auquier P, Bertrand Y, Chastagner P, Kanold J, Poirée M, Thouvenin S, Ducassou S, Plantaz D, Tabone MD, Dalle JH, Gandemer V, Lutz P, Sirvent A, Villes V, Barlogis V, Baruchel A, Leverger G, Berbis J, Michel G. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study. Hae- matologica. 2016;101(6):747-756.
  7. Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, Stovall M, Yasui Y, Nicholson HS, Wolden S, McNeil DE, Mertens AC, Robison LL; Childhood Cancer Survivor Study. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97(3):663-673.
  8. Knijnenburg SL, Raemaekers S, van den Berg H, van Dijk IWEM, Lieverst JA, van der Pal HJ, Jaspers MWM, Caron HN, Kremer LC, van Santen HM. Final height in survivors of childhood cancer compared with height standard deviation scores at diagnosis. Ann Oncol. 2013;24(4):1119-1126.
  9. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr. 2007;150(4):370-375.e1.
  10. Gurney JG, Ness KK, Stovall M, Wolden S, Punyko JA, Neglia JP, Mertens AC, Packer RJ, Robison LL, Sklar CA. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2003;88(10):4731-4739.
  11. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50.
  12. Rose SR, Horne VE, Howell J, Lawson SA, Rutter MM, Trotman GE, Corathers SD. Late endocrine effects of childhood cancer. Nat Rev Endocrinol. 2016;12(6):319-336.
  13. Moëll C, Marky I, Hovi L, Kristinsson J, Rix M, Moe PJ, Garwicz S. Cerebral irradiation causes blunted pubertal growth in girls treated for acute leukemia. Med Pediatr Oncol. 1994;22(6): 375-379.
  14. Cicognani A, Cacciari E, Rosito P, Mancini AF, Carl ȃ G, Mandini M, Paolucci G. Longitudinal growth and final height in long-term survivors of childhood leukaemia. Eur J Pediatr. 1994;153(10): 726-730.
  15. Didcock E, Davies HA, Didi M, Ogilvy Stuart AL, Wales JK, Shalet SM. Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol. 1995;13(10):2503-2507.
  16. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab. 2003;88(8):3682-3689.
  17. Noorda EM, Somers R, van Leeuwen FE, Vulsma T, Behrendt H; Dutch Late Effects Study Group. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer. 2001;37(5):605-612.
  18. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol. 2001;45(5):S176-S182.
  19. Hobbie WL, Mostoufi SM, Carlson CA, Gruccio D, Ginsberg JP. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer. 2011;56(3):474-476.
  20. Steineck A, MacKenzie JD, Twist CJ. Premature physeal closure following 13-cis-retinoic acid and prolonged fenretinide admin- istration in neuroblastoma. Pediatr Blood Cancer. 2016;63(11): 2050-2053.
  21. Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010;17(3):R233-R244.
  22. Viana MB, Vilela MIOP. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer. 2008;50(2, Suppl):509-516.
  23. Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003;21(15):2953-2960.
  24. Shalet SM, Gibson B, Swindell R, Pearson D. Effect of spinal irradiation on growth. Arch Dis Child. 1987;62(5):461-464.
  25. Clayton PE, Shalet SM. The evolution of spinal growth after ir- radiation. Clin Oncol (R Coll Radiol). 1991;3(4):220-222.
  26. Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, Robison LL, Sklar CA. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2004; 89(9):4422-4427.
  27. Wallace WHB, Shalet SM, Morris-Jones PH, Swindell R, Gattamaneni HR. Effect of abdominal irradiation on growth in boys treated for a Wilms' tumor. Med Pediatr Oncol. 1990;18(6): 441-446.
  28. Thomas BC, Stanhope R, Plowman PN, Leiper AD. Growth following single fraction and fractionated total body irradiation for bone marrow transplantation. Eur J Pediatr. 1993;152(11): 888-892.
  29. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Lipsanen M, Tapanainen P. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in prepa- ration for autologous bone marrow transplantation. Bone Mar- row Transplant. 1999;24(10):1131-1136.
  30. Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child. 1995;73(2):141-146.
  31. Papadimitriou A, Urena M, Hamill G, Stanhope R, Leiper AD. Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation. Arch Dis Child. 1991;66(6):689-692.
  32. Cohen LE, Gordon JH, Popovsky EY, Gunawardene S, Duffey- Lind E, Lehmann LE, Diller LR. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014;49(4):502-508.
  33. Ciaccio M, Gil S, Guercio G, Vaiani E, Alderete D, Palladino M, Warman DM, Rivarola MA, Belgorosky A. Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma. Horm Res Paediatr. 2010;73(4):281-286.
  34. Sulmont V, Brauner R, Fontoura M, Rappaport R. Response to growth hormone treatment and final height after cranial or craniospinal irradiation. Acta Paediatr Scand. 1990;79(5): 542-549.
  35. Chow EJ, Liu W, Srivastava K, Leisenring WM, Hayashi RJ, Sklar CA, Stovall M, Robison LL, Baker KS. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer. 2013;60(1):110-115.
  36. Chemaitilly W, Boulad F, Heller G, Kernan NA, Small TN, O'Reilly RJ, Sklar CA. Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transplant. 2007;40(1): 29-35.
  37. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood. 2005; 105(3):1348-1354.
  38. Couto-Silva AC, Trivin C, Esperou H, Michon J, Baruchel A, Lemaire P, Brauner R. Final height and gonad function after total body irradiation during childhood. Bone Marrow Transplant. 2006;38(6):427-432.
  39. Holm K, Nysom K, Rasmussen MH, Hertz H, Jacobsen N, Skakkebaek NE, Krabbe S, M üller J. Growth, growth hormone and final height after BMT. Possible recovery of irradiation- induced growth hormone insufficiency. Bone Marrow Trans- plant. 1996;18(1):163-170.
  40. Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332-1338.
  41. Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, Watanabe A, Hotta N, Ito M, Kurosawa H, Kato K, Tsurusawa M, Horibe K, Shimada H. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159(4):676-681.
  42. Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer. 2012; 59(5):840-845.
  43. Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, Marwaha RK. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/ IGF-1 axis. Pediatr Blood Cancer. 2013;60(7):1148-1153.
  44. Karavitaki N, Brufani C, Warner JT, Adams CBT, Richards P, Ansorge O, Shine B, Turner HE, Wass JAH. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long- term follow-up. Clin Endocrinol (Oxf). 2005;62(4):397-409.
  45. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, M üller J. Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol (Oxf). 2000;53(2): 191-197.
  46. Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM, Barnes N, Armstrong GT, Krasin MJ, Srivastava DK, Pui C-H, Merchant TE, Kun LE, Gajjar A, Hudson MM, Robison LL, Sklar CA. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015; 33(5):492-500.
  47. Kebapcilar L, Bilgir O, Alacacioglu I, Payzin B, Bilgir F, Oner P, Sari I, Calan M, Binicier O. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract. 2009;18(5): 360-363.
  48. Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic my- elogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2011;56(4):671-673.
  49. Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016;85(3): 331-339.
  50. Shalet SM, Beardwell CG, Pearson D, Jones PHM. The effect of varying doses of cerebral irradiation on growth hormone pro- duction in childhood. Clin Endocrinol (Oxf). 1976;5(3):287-290.
  51. Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson BA. Car- diovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993;129(3):195-200.
  52. B ülow B, Hagmar L, Mikoczy Z, Nordstr öm C-H, Erfurth EM. Increased cerebrovascular mortality in patients with hypopitu- itarism. Clin Endocrinol (Oxf). 1997;46(1):75-81.
  53. Kirk JA, Raghupathy P, Stevens MM, Cowell CT, Menser MA, Bergin M, Tink A, Vines RH, Silink M. Growth failure and growth-hormone deficiency after treatment for acute lympho- blastic leukaemia. Lancet. 1987;329(8526):190-193.
  54. Clayton PE, Shalet SM, Morris-Jones PH, Price DA. Growth in children treated for acute lymphoblastic leukaemia. Lancet. 1988; 331(8583):460-462.
  55. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998;83(2): 379-381.
  56. Mukherjee A, Tolhurst-Cleaver S, Ryder WDJ, Smethurst L, Shalet SM. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy. J Clin Endocrinol Metab. 2005;90(3):1542-1549.
  57. Link K, Moëll C, Garwicz S, Cavallin-St åhl E, Bj örk J, Thilén U, Ahrén B, Erfurth EM. Growth hormone deficiency predicts car- diovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89(10): 5003-5012.
  58. Follin C, Thilén U, Österberg K, Bj örk J, Erfurth EM. Cardio- vascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2010;95(8):3726-3735.
  59. van den Heijkant S, Hoorweg-Nijman G, Huisman J, Drent M, van der Pal H, Kaspers G-J, Delemarre-van de Waal H. Effects of growth hormone therapy on bone mass, metabolic balance, and well-being in young adult survivors of childhood acute lym- phoblastic leukemia. J Pediatr Hematol Oncol. 2011;33(6): e231-e238.
  60. Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011; 29(36):4776-4780.
  61. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989;70(262): 145-160.
  62. Lam KSL, Tse VKC, Wang C, Yeung RTT, Ma JTC, Ho JHC. Early effects of cranial irradiation on hypothalamic-pituitary function. J Clin Endocrinol Metab. 1987;64(3):418-424.
  63. Lannering B, Albertsson-Wikland K. Growth hormone release in children after cranial irradiation. Horm Res. 1987;27(1):13-22.
  64. Mulder RL, Kremer LCM, van Santen HM, Ket JL, van Trotsenburg AS, Koning CC, Schouten-van Meeteren AY, Caron HN, Neggers SJ, van Dalen EC. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev. 2009; 35(7):616-632.
  65. Daubenb üchel AM, M üller HL. Neuroendocrine disorders in pediatric craniopharyngioma patients. J Clin Med. 2015;4(3): 389-413.
  66. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, M üller J. Growth hormone response to a growth hormone-releasing hormone stimulation test in a population-based study following cranial irradiation of childhood brain tumors. Horm Res. 2000;54(2):53-59.
  67. Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf). 1998;48(6): 777-783.
  68. Bj örk J, Link K, Erfurth EM. The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH de- ficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation. J Clin Endocrinol Metab. 2005; 90(11):6048-6054.
  69. Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, Youngren NM, Glasser SP, Baker KS. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006;107(6): 1303-1312.
  70. Brennan BMD, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002;118(1):58-66.
  71. Weinzimer SA, Homan SA, Ferry RJ, Moshang T. Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. Clin Endo- crinol (Oxf). 1999;51(3):339-345.
  72. Blijdorp K, van den Heuvel-Eibrink M, Pieters R, Boot A, Sluimer J, van der Lelij A-J, Neggers S. The limited screening value of insulin-like growth factor-I as a marker for alterations in body composition in very long-term adult survivors of childhood cancer. Pediatr Blood Cancer. 2012;59(4):711-716.
  73. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin- like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin- like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6): 361-397.
  74. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990-3993.
  75. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the di- agnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003; 88(1):95-102.
  76. Lissett CA, Saleem S, Rahim A, Brennan BMD, Shalet SM. The impact of irradiation on growth hormone responsiveness to provocative agents is stimulus dependent: results in 161 in- dividuals with radiation damage to the somatotropic axis. J Clin Endocrinol Metab. 2001;86(2):663-668.
  77. Tamhane S, Sfeir JG, Kittah NEN, Jasim S, Chemaitilly W, Cohen LE, Murad MH. GH therapy in childhood cancer survivors: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(8):2794-2801.
  78. Polychronakos C. Laboratory diagnosis of growth hormone de- ficiency in children. In: Cohen LE, ed. Growth Hormone De- ficiency: Physiology and Clinical Management. Cham, Switzerland: Springer International Publishing; 2016:95-107.
  79. Carel JC, Tresca JP, Letrait M, Chaussain JL, Lebouc Y, Job JC, Coste J. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register-based study. J Clin Endocrinol Metab. 1997;82(7):2117-2121.
  80. Blatt J, Bercu BB, Gillin JC, Mendelson WB, Poplack DG. Re- duced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr. 1984;104(2): 182-186.
  81. Darzy KH, Pezzoli SS, Thorner MO, Shalet SM. Cranial irradi- ation and growth hormone neurosecretory dysfunction: a critical appraisal. J Clin Endocrinol Metab. 2007;92(5):1666-1672.
  82. Corneli G, Di Somma C, Prodam F, Bellone J, Bellone S, Gasco V, Baldelli R, Rovere S, Schneider HJ, Gargantini L, Gastaldi R, Ghizzoni L, Valle D, Salerno M, Colao A, Bona G, Ghigo E, Maghnie M, Aimaretti G. Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol. 2007;157(6):701-708.
  83. Yuen KC. Laboratory diagnosis of growth hormone deficiency in adults. In: Cohen LE, ed. Growth Hormone Deficiency: Physi- ology and Clinical Management. Cham, Switzerland: Springer International Publishing; 2016:109-121.
  84. Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, Gurel MH, Sluss PM, Biller BM, Miller KK. Overweight/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. J Clin Endocrinol Metab. 2014;99(12):4712-4719.
  85. Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic- pituitary-adrenal axes in adults: results from a prospective ran- domized multicenter study. Pituitary. 2016;19(3):332-341.
  86. Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, K örner A, Obermayer-Pietsch B, H übener C, Dahlgren J, Frystyk J, Pfeiffer AF, Doering A, Bielohuby M, Wallaschofski H, Arafat AM. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF- I immunoassay conforming to recent international recommen- dations. J Clin Endocrinol Metab. 2014;99(5):1712-1721.
  87. Elmlinger MW, K ühnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 2004;42(6):654-664.
  88. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Smethurst LE, Shalet SM. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf). 1999;51(5):565-573.
  89. Chemaitilly W, Robison LL. Safety of growth hormone treatment in patients previously treated for cancer. Endocrinol Metab Clin North Am. 2012;41(4):785-792.
  90. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21): 1528-1537.
  91. Strodtbeck K, Sloan A, Rogers L, Fisher PG, Stearns D, Campbell L, Barnholtz-Sloan J. Risk of subsequent cancer following a primary CNS tumor. J Neurooncol. 2013;112(2):285-295.
  92. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136-3141.
  93. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, Blum WF, Robison LL; GeNeSIS and HypoCCS International Advisory Boards. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013; 168(4):565-573.
  94. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494-3498. 100. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, Armstrong GT, Meadows A, Stovall M, Robison LL, Meacham LR. Growth hormone exposure as a risk factor for the devel- opment of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99(6):2030-2037. 101.
  95. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96(9): 2756-2761. 102.
  96. Brignardello E, Felicetti F, Castiglione A, Fortunati N, Matarazzo P, Biasin E, Sacerdote C, Ricardi U, Fagioli F, Corrias A, Arvat E. GH replacement therapy and second neoplasms in adult survivors of childhood cancer: a retrospective study from a single in- stitution. J Endocrinol Invest. 2015;38(2):171-176. 103. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger C, Swerdlow A, Thorner M. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2): 1-9. 104. M üller HL, Gebhardt U, Schr öder S, Pohl F, Kortmann RD, Faldum A, Zwiener I, Warmuth-Metz M, Pietsch T, Calaminus G, Kolb R, Wiegand C, S örensen N; study committee of KRA- NIOPHARYNGEOM 2000/2007. Analyses of treatment vari- ables for patients with childhood craniopharyngioma-results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up. Horm Res Paediatr. 2010;73(3): 175-180. 105. Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handb Clin Neurol. 2016;134:329-344. 106. Mostoufi-Moab S, Isaacoff EJ, Spiegel D, Gruccio D, Ginsberg JP, Hobbie W, Shults J, Leonard MB. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. Pediatr Blood Cancer. 2013;60(11):1766-1771. 107.
  97. Oudin C, Auquier P, Bertrand Y, Contet A, Kanold J, Sirvent N, Thouvenin S, Tabone MD, Lutz P, Ducassou S, Plantaz D, Dalle JH, Gandemer V, Beliard S, Berbis J, Vercasson C, Barlogis V, Baruchel A, Leverger G, Michel G. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study. Bone Marrow Transplant. 2015;50(11):1438-1444. 108. Faienza MF, Delvecchio M, Giordano P, Cavallo L, Grano M, Brunetti G, Ventura A. Metabolic syndrome in childhood leukemia survivors: a meta-analysis. Endocrine. 2015;49(2): 353-360. 109. Chemaitilly W, Merchant TE, Li Z, Barnes N, Armstrong GT, Ness KK, Pui CH, Kun LE, Robison LL, Hudson MM, Sklar CA, Gajjar A. Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tu- mours: presentation and long-term outcomes. Clin Endocrinol (Oxf). 2016;84(3):361-371. 110. Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, Leisenring W, Robison LL, Sklar CA. Abnormal timing of menarche in survivors of central nervous system tumors: a report from the Childhood Cancer Survivor Study. Cancer. 2009; 115(11):2562-2570. 111. Gan H-W, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787-3799. 112. Mensah FK, Bayer JK, Wake M, Carlin JB, Allen NB, Patton GC. Early puberty and childhood social and behavioral adjustment. J Adolesc Health. 2013;53(1):118-124. 113. Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, Zerah M, Brauner R. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf). 2006;65(2):239-245. 114. Rivarola MA, Belgorosky A, Mendilaharzu H, Vidal G. Pre- cocious puberty in children with tumours of the suprasellar and pineal areas: organic central precocious puberty. Acta Paediatr. 2001;90(7):751-756. 115. Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr. 1995;126(3):364-367. 116. Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, Levine LS, Sklar CA. Age at onset of puberty following high- dose central nervous system radiation therapy. Arch Pediatr Adolesc Med. 1996;150(6):589-592. 117. Sklar CA, Robison LL, Nesbit ME, Sather HN, Meadows AT, Ortega JA, Kim TH, Hammond GD. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990;8(12):1981-1987. 118. Siimes MA, Rautonen J. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies. Cancer. 1990;65(6):1303-1306. 119.
  98. Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kato S. Gonadal shielding to irradiation is ef- fective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant. 2007;39(8):483-490. 120. Romerius P, St åhl O, Moëll C, Relander T, Cavallin-St åhl E, Wiebe T, Giwercman YL, Giwercman A. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab. 2009; 94(11):4180-4186. 121. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM; ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin- releasing hormone analogs in children. Pediatrics. 2009;123(4): e752-e762. 122. de Vries L, Phillip M. Role of pelvic ultrasound in girls with precocious puberty. Horm Res Paediatr. 2011;75(2):148-152. 123.
  99. Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R. Neurofibromatosis type 1 growth charts. Am J Med Genet. 1999; 87(4):317-323. 124. Garibaldi LR, Aceto T Jr, Weber C, Pang S. The relationship between luteinizing hormone and estradiol secretion in female precocious pu- berty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J Clin Endocrinol Metab. 1993;76(4):851-856. 125. Ib áñ ez L, Potau N, Zampolli M, Virdis R, Gussinyé M, Carrascosa A, Saenger P, Vicens-Calvet E. Use of leuprolide ac- etate response patterns in the early diagnosis of pubertal disor- ders: comparison with the gonadotropin-releasing hormone test. J Clin Endocrinol Metab. 1994;78(1):30-35. 126. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of pre- cocious puberty. J Pediatr. 1995;127(1):47-52. 127. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. A report of 96 cases. Am J Dis Child. 1968;115(3):309-321. 128.
  100. Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJM, van den Brekel MW, Breunis WB, Chang YC, Davila Fajardo R, Dunaway D, Gajdosova E, Gaze MN, Gupta S, Hartley B, Kremer LCM, van Lennep M, Levitt GA, Mandeville HC, Pieters BR, Saeed P, Smeele LE, Strackee SD, Ronckers CM, Caron HN, van Santen HM, Merks JHM. Endocrine disorders among long-term survivors of childhood head and neck rhab- domyosarcoma. Eur J Cancer. 2016;54:1-10. 150. Ratnasingam J, Karim N, Paramasivam SS, Ibrahim L, Lim LL, Tan ATB, Vethakkan SR, Jalaludin A, Chan SP. Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors. Pituitary. 2015;18(4):448-455. 151.

Cited by

Sorted by citations

Authors
Sklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • St. Jude Children's Research Hospital (US)
  • Boston Children's Hospital (US)
  • Skåne University Hospital (SE)
  • Emory University (US)
  • Mayo Clinic (US)
Corresponding author
Sklar, Charles A
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2018-06-29
Volume
103
Issue
8
Pages
2761-2784
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2018-01175
OpenAlex
W2810587994
Cited by
224
References
10
Citations by year
2026: 27 · 2025: 23 · 2024: 27 · 2023: 21 · 2022: 35 · 2021: 25 · 2020: 33 · 2019: 28 · 2018: 3
FWCI
24.57
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Memorial Sloan-Kettering Cancer Center
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
childhood cancer survivors, hypothalamic-pituitary dysfunction, growth disorders, pituitary dysfunction, growth hormone deficiency, hypopituitarism, endocrine surveillance, endocrine therapy, late effects of cancer treatment
MeSH terms
Cancer Survivors, Adult, Child, Female, Growth Disorders, Humans, Hypothalamic Diseases, Hypothalamo-Hypophyseal System, Male, Neoplasms, Palliative Care, Pituitary Diseases, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review